February 04, 2014
1 min read

Genetic variants associated with lutein, zeaxanthin in AMD

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Several genetic variants were associated with the role of lutein and zeaxanthin in reducing the risk of age-related macular degeneration, according to a large study.

Data were culled from the Carotenoids in Age-Related Eye Disease Study (CAREDS). The study subset included 1,663 of 2,005 CAREDS participants who were genotyped for 424 single nucleotide polymorphisms (SNPs) from 24 candidate genes.

Ninety-one percent of 337 AMD cases had early or intermediate AMD. Investigators used a logistic regression model to test SNPs for associations with AMD.

Results showed that 24 SNPs from nine carotenoid-candidate genes — BCMO1, BCO2, NPCL1L1, ABCG8, FADS2, SCARB1, ABCA1, APOE and ALDH3A2 — were associated with AMD, independent of age and ancestry.

Variants in all genes except BCO2 and FADS2 were associated with the presence of lutein and zeaxanthin in blood serum or the macula.

Nine variants discriminated between AMD cases, independent of age, smoking status, CFH Y402H and ARMS2 A69S (P = .002).

Disclosure: Johnson has a financial relationship with Bausch + Lomb. The remaining authors have no relevant financial disclosures.